REG - ReNeuron Group plc - Director Change

ReNeuronAnnouncement

11/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220211:nRSK3606Ba&default-theme=true

RNS Number : 3606B  ReNeuron Group plc  11 February 2022

 
ReNeuron Group plc

("ReNeuron" or the "Company")

 

Director Change

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes
Technologies, announces that Olav Hellebø is standing down as CEO and
executive director of the Company and will leave the Company on 28 February
2022.

 

With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO
and the leadership team, will assume responsibility for the running of the
business as the Company transitions to focus primarily on the development of
its Exosome Technology Platform.

 

Olav Hellebø, commented: "Following ReNeuron's recent change in strategy, the
time has come for me to pursue other opportunities. I would like to thank
employees and other stakeholders who have been instrumental in pursuing our
pioneering technologies over many years."

 

Iain Ross, Chairman of ReNeuron, commented: "On behalf of the Board and
Management I would like to recognise Olav's contribution to the Company over
the last 7 years and wish him well in the future."

 

 Further announcements will be made in due course.

 

 
ENDS

 

 

 

Contacts:

 

 ReNeuron                                                 www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                                      Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)  +44 (0)20 7710 7600

 Ben Maddison, Stewart Wallace

 Allenby Capital Limited (Joint Broker)                   +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                 +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus/Alice Woodings                              +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

 

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company also has a Phase 2 cell therapy candidate in retinitis pigmentosa
which it plans to out-license and also has out-licensed its CTX programme in
stroke disability to Fosun in China.

 

ReNeuron's shares are traded on the London AIM market under the symbol
RENE.L.  For further information visit www.reneuron.com
(http://www.reneuron.com)

 

This announcement contains inside information. The person responsible for
arranging for the release of this announcement on behalf of the Company is
Catherine Isted, Chief Financial Officer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASFFFASEESEDE